
A | Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。 中新网阿坝8月25日电 题:“死亡之海”变“生命绿洲” 长征红铺就红原富民路 作者 王利文 8月的四川阿坝红原县日干乔大沼泽,草色青翠接天,云影徘徊于水泽之间。游客们举着手机寻找最佳角度,将蓝天、绿草与沼泽的倒影定格成画。很少有人注意到,脚下这片世界上最大的高原湿地之一,曾是红军长征途中最为凶险的“死亡之海”。 “1936年,红二、四方面军左路纵队从这里穿越,一万多名将士因饥饿、寒冷、伤病长眠于周边的茫茫草海。”红原县政协文史提案委主任贺建军站在红军过草地纪念碑前,声音低沉。2005年,红原日干乔红军长征纪念遗址被列为全国红色旅游经典景区之一,2020年又被列为四川省第九批省级文物保护单位。如今,它既是爱国主义教育基地,也是影视拍摄基地。 8月24日,四川阿坝红原县一处民居。记者 韩海丹 摄 历史的厚重与当下的轻盈,在这片高原湿地奇妙交织。

B | 牧民桑吉骑着马,吆喝着招揽游客前来体验。

C | 这位“Z世代”年轻人,家中拥有近300头牛与10多匹马,旺季日均接待骑行游客一两百人。 “红原是红军走过的草原。

D | ”桑吉向游客讲述时,常从地名渊源切入。他希望越来越多的游客来到家乡感受美丽风景和厚重历史,这种朴素理念背后,是草原牧民对红色文化的深层认同。“红军曾经走过,为现在带来了发展机遇。”作为年轻一代,桑吉正尝试用AI工具制作短视频,让长征故事触达更多屏幕前的目光。

E | 8月24日,四川阿坝红原县,红军过草地纪念碑。记者 韩海丹 摄 从日干乔到县城邛溪镇热坤村,隐丛乡村度假酒店里咖啡香气与草原清风混合。窗外,牦牛在湖泊边悠闲吃草,阳光洒落木质露台。店长尕尔让透露,旺季客房入住率超98%,甚至有来自港澳台及日韩等地的客人慕名而来。这家“野奢”风格的精品酒店,是村集体经济项目。 2021年,热坤村党支部依托东西部协作,引进浙江企业,总投资1500万元打造该项目。每年租金逾20万元且逐年递增,提供稳定岗位10余个,带动全村人均增收500元。8月音乐节期间一房难求,溢出客流惠及县城及周边私人民宿。 8月24日,四川阿坝红原县一处民宿。

F | 记者 韩海丹 摄 “很多中高端游客专程来体验红色文化,暑期带着孩子走长征路。”邛溪镇党委副书记何思斌道出文旅融合的核心逻辑。红色文化是当地文旅最大底色,从江西瑞金出发的亲子研学队伍,沿长征路线一路向西,经若尔盖至甘肃,红原正是这条精神脉络上的关键节点。 文化牵引力跨越国界。来自以色列和意大利的伽利·韦尔·博亚尔斯基一家四口专程到访。“令人惊叹”,这是他们对红原景观的第一评价;建筑色彩、文化氛围与民众热情,则构成更深层的文化吸引力。 2025年红原县政府工作报告显示,过去五年,当地累计接待游客1299万人次,旅游收入106.26亿元。雅克音乐季持续火爆,3个国家3A级景区、4个州级特色旅游名镇名村相继创建。

G | 与此同时,红原草原植被综合盖度稳定在86.3%,空气质量稳居四川“第一方阵”,林草碳汇项目更使红原荣膺“四川省林草碳汇第一县”。

H | 生态保护与经济发展的平衡,在红色文化中找到支点,让“死亡之海”真正转化为“生命绿洲”。 夕阳西下,日干乔大沼泽的倒影从湛蓝渐变为金红,桑吉牵马归家,民宿亮起暖黄灯光。红色记忆转化为绿色发展的动能,历史沉淀孕育出民生福祉。

I | (完) 【编辑:何颖】。

J |
Current article:http://1qu.wengsengzhanhuangu.cyou/bmbco3g/20260826/13136.html
Published on:08:30:26
国内/08-23
国内/08-24
国内/08-25
国内/08-25
国内/08-23
国内/08-26
国内/08-25
国内/08-23
国内/08-23